Olanzapine is indicated for the treatment of schizophrenia.
In patients who initially responded to treatment, olanzapine has demonstrated its effectiveness in maintaining this clinical improvement over the long term.
Olanzapine is indicated for the treatment of moderate to severe manic episodes.
Olanzapine is indicated for the prevention of relapses in patients with bipolar disorder who have previously responded to olanzapine treatment during a manic episode.
| Specialty | OLANZA ODT |
|---|---|
| Dosage | 10 mg |
| Form | Orodispersible tablet |
| Presentation | Box of 30 |
| Primary packaging | Blister |
| Specification | ALU, PA, PVC |
| INN | OLANZAPINE |
| VEIC Classification | Essential |
| Therapeutic Class | NERVOUS SYSTEM |
| Subclass | PSYCHOLEPTICS |
| Laboratory | PHILADELPHIA PHARMA |
| Schedule | A |
| Shelf life | 2 years |
| Generic/Originator | Generic |
| Marketing Authorization Number (MA) | 9353311 |
| Marketing Authorization Date | 26/03/2026 |
| Product Range | NeuroPsy |
You must be logged in to post a review.
Reviews
There are no reviews yet.